EDSA Stock Analysis: Buy, Sell, or Hold?
EDSA - Edesa Biotech, Inc. Common Shares
$4.23
-0.43 (-9.23%)
▼
5d:
-11.13%
30d:
-20.19%
90d:
-25.13%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When EDSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EDSA is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EDSA is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EDSA is currently trading at $4.23, which is considered oversold relative to its 30-day fair value range of $4.53 to $5.37.
Technical Outlook: Technically, EDSA is in a strong downtrend. The price is currently testing key support at $4.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $16.33 (+286.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDSA is in a strong downtrend. The price is currently testing key support at $4.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $16.33 (+286.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.53 -
$5.37
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.2%)
- BULLISH: Trading 286.1% below Wall St target ($16.33)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.53 -
$5.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.23
Resistance Level
$5.10
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.05
Wall Street Target
$16.33
(+286.1%)
Revenue Growth (YoY)
-99.9%
Share & Embed Analysis
Last updated: September 13, 2026 6:09 AM ET
Data refreshes hourly during market hours. Next update: 7:09 AM
Data refreshes hourly during market hours. Next update: 7:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
